BACKGROUND: Co-existent cardiac and renal dysfunction is increasingly recognized as both a predictor and mediator of poor outcomes in patients with advanced heart failure. Novel therapies, including adenosine receptor antagonists, are currently under development for the treatment of 'cardiorenal syndrome'. OBJECTIVES: To review the pathophysiologic rationale for using rolofylline, a selective adenosine 1 receptor antagonist, in patients with cardiorenal syndrome; and to provide a critical overview of safety and efficacy data from clinical studies. METHODS: We reviewed published data on the pharmacology of rolofylline, and used this to inform a comprehensive summary of preclinical and clinical trials. Cardiac and renal effects, and safety data with a particular reference to seizures, are highlighted. RESULTS/CONCLUSION: Rolofylline facilitates diuresis and preserves renal function in patients with acute decompensated heart failure and renal dysfunction. Pilot data also suggest beneficial effects on symptoms and short-term outcomes. The risk of seizures may be minimized by excluding high-risk patients.
Rolofylline: A selective adenosine 1 receptor antagonist for the treatment of heart failureAll Scholarly Works
Document TypeArticle, Peer-reviewed
Citation InformationSlawsky MT, Givertz MM. Rolofylline: A selective adenosine 1 receptor antagonist for the treatment of heart failure Expert Opin Pharmacother 2009 Feb;10(2):311-22.